Group 1 - In January, the A-share market saw increased trading activity and risk appetite, with all three major indices achieving gains, notably the Shanghai Composite Index rising by 3.76% and the CSI 500 Index increasing by 12.12% [1] - The rise in cyclical industries such as precious metals, non-ferrous metals, chemicals, and oil and gas was driven by multiple factors including complex international dynamics, a weakening US dollar, and domestic industrial policy support, although there was significant volatility at the end of the month [1] - The technology sector, particularly AI applications, is expected to enter a critical validation window as large model technologies mature, with strong demand for computing power and investments in AI hardware like storage chips and semiconductor equipment [1] Group 2 - As of January 2026, the total number of bank wealth management products in the market reached 46,845, an increase of 553 from December 2025, with fixed-income products making up the majority at 43,215 [2] - In January, 2,969 new wealth management products were launched, a decrease of 305 from the previous month, with wealth management subsidiaries of banks accounting for 76.56% of the new issuances [2] - The overall risk level of wealth management products in January increased significantly, with 51 products rated as medium risk and 4 additional products rated as medium-high risk compared to the previous month [12] Group 3 - The asset allocation of wealth management products in January showed a high proportion of bonds and public funds, with a focus on cash, bank deposits, and short-term bond ETFs for liquidity and low risk [17] - Mixed wealth management products had diverse asset allocations, covering debt, convertible bonds, equity assets, and gold, with many products cautiously investing in gold ETFs to capture commodity investment opportunities [18] - The top five institutions accounted for 43.81% of the products listed, indicating a competitive advantage for state-owned and joint-stock bank wealth management subsidiaries [14]

Core Viewpoint - MiniMax has achieved a market capitalization exceeding 200 billion HKD since its listing on the Hong Kong stock exchange, driven by the launch of its new model M2.5, which has garnered significant market attention and investor returns [2][3]. Group 1: MiniMax's Market Performance - MiniMax's stock price surged over 13% on February 13, 2023, following the announcement of its M2.5 model, which is comparable to Claude Opus 4.6 in performance [3]. - The company reached a market valuation of over 200 billion HKD shortly after its IPO, marking a significant milestone in the tech industry [2][3]. Group 2: Investment Landscape - MiHoYo, a gaming company, was a key angel investor in MiniMax, investing at a post-money valuation of 200 million USD, and has seen its investment return exceed 100 times [4][5]. - Other notable investors in MiniMax include Hillhouse Capital, IDG Capital, Sequoia China, Alibaba, Tencent, and several others, indicating a strong backing from prominent venture capital firms [5]. Group 3: MiHoYo's Financial Contributions - MiHoYo has disclosed that it will contribute a total tax of 150 billion CNY over five years from 2021 to 2025, showcasing its significant financial impact [10][11]. - The company's tax contributions have increased from 1.8 billion CNY in 2021 to a projected 150 billion CNY by 2025, reflecting its rapid revenue growth [10]. Group 4: MiHoYo's Investment Strategy - MiHoYo has diversified its investment portfolio, backing various innovative projects, including brain-computer interfaces and private space ventures, indicating a forward-thinking investment approach [12][13]. - The company has positioned itself as a significant player in the venture capital space, actively engaging with young, tech-driven entrepreneurs [13].

联系人：李智 河南资本市场月报 分析师：李济生 登记编码：S0730522100002 lijs@ccnew.com 分析师：郑婷 登记编码：S0730524110001 zhengting@ccnew.com 相关报告 《河南资本市场月报（2026 年第 1 期）》 2026-1-15 《河南资本市场月报（2025 年第 11 期）》 2025-12-9 （2026 年第 2 期） 证券研究报告 发布日期：2026 年 2 月 13 日 投资要点： 风险提示：全球贸易和产业管制政策带来的不确定性风险；经济增长和 业绩不及预期；市场流动性风险。 本报告版权属于中原证券研究所股份有限公司 www.ccnew.com 请阅读最后一页各项声明 第 1页/共 20页 电话： 0371-65585629 地址： 郑州郑东新区商务外环路10号18楼 地址： 上海浦东新区世纪大道 1788 号 T1 座 22 楼 经济运行情况：2025 年，我国国内生产总值达到 1401879 亿元，比 上年增长 5.0%，经济增速目标圆满完成；2025 年河南省 GDP 达到 66632.79亿元，总规模位居全国第六、中部第一，GDP同 ...

Group 1 - Aihua Long faces regulatory scrutiny after being warned about its involvement in the brain-machine interface sector, leading to a formal investigation and losses in both its main business and stock trading activities [1] - Rongbai Technology's order value plummeted from 120 billion to a fine of 9.5 million due to false disclosures, with Chairman Bai Houshan fined 3 million [1] - BYD aims to sell 1.3 million vehicles overseas by 2026, contributing to China's export of over 7 million vehicles, marking a third consecutive year of global leadership in this sector [1] Group 2 - Haichang Intelligent has accounts receivable of 450 million, accounting for 56% of its revenue, and is involved in a patent lawsuit that may result in a compensation of 10.83 million [1] - Zhiji Motors has set a target of selling 81,000 vehicles by 2025 but has failed to meet its targets for three consecutive years, with CEO Liu Tao apologizing for safety concerns related to Tesla [1] - China Shenhua's restructuring plan, involving the acquisition of 12 companies, was approved in just six days, with a total value of 133.6 billion [1] Group 3 - Changchun High-tech anticipates a loss of 1 billion in the fourth quarter due to product price adjustments, while investing over 2 billion annually in R&D to reduce reliance on growth hormones [1] - Vanke's losses are expected to deepen, projecting a loss of 82 billion by 2025, with a bond extension of 6.8 billion and additional support of 2.36 billion from Shentie [1] - GAC Group has issued a rare profit warning, expecting losses between 8 billion to 9 billion, with CEO Feng Xingya reiterating the focus on three major battles for a turnaround [1] Group 4 - Nanhai Rural Commercial Bank was fined 3.8 million, with its net interest margin dropping to 1.15% after eight years of unsuccessful A-share market attempts [1] - Yuanji Food is closing one out of every three new stores, with Yuan Lianghong's wife holding shares in six supplier companies involved in related transactions worth 130 million [1] - "Cheese Queen" Chai Xiu has exited the market after costly marketing efforts, leading to a 70% drop in the stock price of Miaokelan Duo, with Mengniu taking full control [1] Group 5 - Zijin Mining has invested an additional 28 billion in overseas acquisitions, projecting a profit of 51 billion by 2025, with its market value stabilizing above 1 trillion [1] - Hunan Gold's restructuring of 2.7 billion in assets aims to increase resource reserves, benefiting from rising prices of antimony and tungsten, resulting in record profits exceeding 1.27 billion [1] - A shareholder named Yu Han was penalized over 1 billion for manipulating stock prices, while Doctor's Optical spent 50 million on traffic acquisition but only 3 million on R&D [1] Group 6 - SAIC-GM-Wuling's debt ratio has risen to 85.24%, despite a 20.5% increase in sales, which remains 53.5 thousand units below its peak [1]

Core Viewpoint - Yahua Electronics (301337) is experiencing a concentration of shareholders, with a forecast for 2025 indicating a narrowing of losses, progress in brain-computer interface (BCI) business, and delays in some fundraising projects [1][2][3][4][5] Shareholder Concentration - As of January 31, 2026, the number of shareholders decreased to 12,161, a reduction of 668 shareholders or 5.21% compared to January 20, indicating a trend of concentration [2] Financial Performance - The company forecasts 2025 revenue between 250 million to 270 million yuan, with a net loss attributable to shareholders expected to be between 12 million to 17 million yuan, representing a reduction in losses by 35.82% to 54.69% year-on-year [3] Business Development - Progress has been made in the brain-computer interface business, with the initial integration of BCI and smart ward systems completed, leading to the launch of a brain-smart ward solution [4] Project Updates - The company announced delays in the "Research and Development Center Construction Project" and "Marketing Network Construction Project," with the expected usable status date pushed to December 31, 2027, to adapt to market changes and mitigate risks [5]

经济观察网麦澜德于2026年2月11日发生大规模限售股解禁，解禁数量为6317.32万股，占总股本的 63.17%，解禁后公司已无限售股份流通。基于最新股价44.46元(截至2026年2月13日数据)，解禁市值约 28.08亿元。本次解禁涉及6名原始股东，均为首发原股东限售股份。 减持压力方面，解禁比例极高，若股东集中减持，可能加剧股价波动。历史数据显示，解禁后股东户数 环比增加17.23%(截至2026年2月11日)，市场分歧可能扩大。市场环境方面，A股医疗器械板块近期震荡 (如2026年2月13日医疗器械板块涨跌幅为0%)，解禁个股易受整体情绪影响。本次解禁需重点关注股东 减持动向与公司基本面匹配度。麦澜德在细分领域具备技术壁垒，但解禁带来的流动性冲击不容忽视。 事件影响 以上内容基于公开资料整理，不构成投资建议。 高比例解禁可能显著增加股份供给，原始股东减持压力较大，需警惕股价短期波动风险。从公司基本面 看：财务表现方面，2025年前三季度营收3.44亿元(同比+4.01%)，归母净利润0.96亿元(同比-0.07%)，毛 利率70.05%，负债率9.52%，显示盈利稳健但增长放缓。业务布局方面，公司聚 ...

Group 1 - The core viewpoint of the news highlights the mixed performance of the constituents of the CSI Pharmaceutical and Medical Device Innovation Index, with Pizhou Pharmaceutical leading the gains at 1.08% and Xinhengcheng leading the losses [1] - The Medical Innovation ETF (516820) is currently priced at 0.36 yuan, with a turnover rate of 0.63% and a transaction volume of 11.7 million yuan during the trading session [1] - Over the past month, the average daily transaction volume of the Medical Innovation ETF reached 62.8 million yuan [1] Group 2 - Brain Tiger Technology has successfully implanted a fully wireless brain-computer interface in its first clinical patient, who can now perform daily activities such as shopping and sending red envelopes through thought control [1] - According to Jiao Yin International Securities, the pharmaceutical industry is expected to continue shifting towards innovative drugs and high clinical value products due to ongoing medical insurance cost control and centralized procurement [1] - The market sentiment has improved, and significant business development transactions are driving strong performance in the pharmaceutical sector, with a stable outlook expected to continue into 2026 despite potential short-term volatility [1] Group 3 - The CSI Pharmaceutical and Medical Device Innovation Index consists of 30 publicly listed companies with good profitability, growth potential, and research innovation capabilities, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Hengrui Medicine, accounting for a total of 63.9% of the index [2]

二是政策扶持不同，新能源汽车是十四五重点发力的新兴产业，有牌照、补贴、购置税减免等多重利 好，而脑机接口并无这类政策支持。 做投资本就该结合产业研究 + 产业链规模 + 政策红利，三者共振，才能走出大行情。 马斯克旗下九大版图，特斯拉、AI 算力都已大幅上涨，凭什么商业航天不能走出大行情？ 再看脑机接口，此前涨幅远不及特斯拉、AI，核心原因很清晰： 一是产业链太短，脑机接口本质就是采集脑电波的头盔 + 控制假肢，零部件极少；对比汽车工业上万 零部件，产业链规模差距极大。 当下核心看赛道，重点就是航天领域，尤其商业航天。 若把握不准节奏，也可关注券商，虽有机会但爆发力一般；切记券商千万别追突破，突破多半是套人， 选标的就挑低价券商。 要是问券商和商业航天选哪个？无疑是商业航天（火箭、星链）更具潜力。 ...

经济观察网博拓生物股价在2026年2月13日出现上涨，可能与公司近期披露的业绩预告及对未来发展的 积极展望有关。 公司在脑机接口领域的战略布局也受到市场关注。根据证券时报网2026年1月25日的报道，公司正通过 旗下产投平台深度参与脑机接口产业，并已战略入股相关企业，试图打造第二增长曲线。 股票近期走势 截至2026年2月13日11:19更新行情数据显示，博拓生物股价当日上涨5.36%，而所属的医疗器械板块指 数当日下跌0.18%，显示其走势显著强于板块整体表现。 以上内容基于公开资料整理，不构成投资建议。 业绩经营情况 公司于2026年1月23日发布的2025年度业绩预告显示，尽管预计全年归母净利润同比出现较大幅度下 滑，但管理层在后续的投资者交流活动中明确表示，随着中美关税环境趋于稳定，以及公司差异化竞争 产品在多个市场陆续获证，对2026年营业收入实现稳步增长抱有信心。这种"短期业绩承压，但未来增 长拐点可期"的预期可能对市场情绪产生了积极影响。 战略推进 ...

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for Heng Rui Pharmaceutical (600276) and "Increase" for WuXi Biologics (603259) [46] Core Insights - The recent national drug procurement has been stable, with active participation from companies and continued benefits for patients [8][9] - The issuance of the "National Basic Drug Directory Management Measures" aims to enhance the management of essential medicines [10][11] - Heng Rui Pharmaceutical reported positive top-line results for its GLP-1/GIP dual receptor agonist, indicating significant weight loss in clinical trials [12] - The approval of Mu Feng Da® for the treatment of adult type 2 diabetes marks a significant development in the market [12] Industry News - The national drug procurement involved 316 commonly used drugs across 26 therapeutic areas, with a high participation rate from over 5,100 medical institutions and 1,091 companies [8][9] - The procurement process has been standardized, allowing companies to bid online once for nationwide sales, significantly reducing costs [9] - The management measures for the national basic drug directory have been revised to include legal policy bases and optimize the directory structure [10][11] Company Announcements - Innovent Biologics has entered a global strategic partnership with Eli Lilly to advance new drug development in oncology and immunology [26] - Kelun Pharmaceutical's TROP2 ADC has received approval for a fourth indication from the NMPA [27] - Heng Rui Pharmaceutical's drug has been included in the list of breakthrough therapy products, and its application for marketing approval has been accepted for priority review [28] - WuXi Biologics has forecasted a positive earnings outlook, expecting a revenue increase of approximately 16.7% [30] Market Review - The Shanghai Composite Index rose by 1.43%, while the Shenzhen Component Index increased by 2.37%, with the SW Pharmaceutical and Biotech Index up by 0.23% [36] - The industry’s price-to-earnings ratio (TTM) stands at 51.17, with a valuation premium of 259% compared to the CSI 300 [40] Weekly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring performance recovery indicators [46]